Ergosterol nano dispersion as well as preparation method and application thereof

Abstract

The invention provides an ergosterol nano-dispersion and a preparation method and application thereof, the ergosterol nano-dispersion comprises an ergosterol core material and a soybean protein isolate wall material wrapping at least part of the surface of the ergosterol core material, the particle size of the dispersion is 250-400 nm, and the PDI of the dispersion is 0.034-0.106. Due to the special composition and related parameters of the dispersion, the dispersity, uniformity and bioaccessibility of the ergosterol in water are remarkably improved.

Description

Technical Field

[0001] This application relates to the technical field of natural product utilization, and particularly relates to an ergosterol nano-dispersion, a preparation method thereof, and an application thereof. Background Art

[0002] Ergosterol is an important bioactive compound that widely exists in various food sources, such as mushrooms and yeasts. It not only plays a key role in enhancing immunity but also helps neutralize free radicals in the body through its strong antioxidant properties, thereby protecting cells from oxidative damage. In addition, the antibacterial function of ergosterol makes it a natural barrier against various pathogens.

[0003] More importantly, ergosterol shows significant efficacy in regulating blood lipids. Research shows that it can intervene in the cholesterol metabolism pathway, inhibit the synthesis and absorption of cholesterol. At the same time, ergosterol can regulate the gene expression related to cholesterol metabolism, thereby reducing the absorption of cholesterol in the intestine. This mechanism not only helps to reduce the concentration of cholesterol in the blood but also may have a positive impact on preventing cardiovascular diseases.

[0004] Therefore, increasing the intake of ergosterol through dietary supplements may be an effective strategy for those with abnormal blood lipids or at risk of cardiovascular diseases. Regular intake of foods or supplements rich in ergosterol not only helps maintain a healthy cholesterol level but also contributes to the improvement of overall cardiovascular health. Combined with a healthy lifestyle and eating habits, the supplementation of ergosterol may become an important part of preventing and managing abnormal blood lipids.

[0005] However, due to its extremely low water solubility, ergosterol is difficult to be uniformly dispersed in a conventional aqueous phase system, which limits its applications in the fields of food, medicine, etc. In addition, the poor bioaccessibility of this compound leads to low efficiency in the process of human digestion and absorption, further reducing the exertion of its physiological activity. Summary of the Invention

[0006] This application provides an ergosterol nano-dispersion, which significantly improves the dispersibility, homogeneity, and bioaccessibility of ergosterol in water by defining its composition and related parameters.

[0007] This application also provides a preparation method of the above-mentioned ergosterol nano-dispersion, which can effectively improve the problems of poor dispersibility, poor homogeneity, and poor bioaccessibility of ergosterol in water.

[0008] This application also provides an ergosterol nano-dispersion solution, in which the dispersion is more uniform and is applicable to lipid-lowering drugs.

[0009] This application also provides a lipid-lowering drug, which has a better lipid-lowering effect.

[0010] The present application provides an ergosterol nano-dispersion, which comprises an ergosterol core material and a soy protein isolate wall material that coats at least a part of the surface of the ergosterol core material. The particle size of the dispersion is 250 - 400 nm, and the PDI of the dispersion is 0.034 - 0.106.

[0011] The dispersed particles of the nano-dispersion as described above are spherical or quasi-spherical.

[0012] The present application also provides a preparation method of the ergosterol nano-dispersion according to any one of the above, comprising the following steps:

[0013] After homogenizing a mixed emulsion comprising ergosterol and soy protein isolate, a precursor of the ergosterol nano-dispersion is obtained. After centrifuging the precursor of the ergosterol nano-dispersion, an ergosterol nano-dispersion is obtained.

[0014] For the preparation method as described above, the mixed emulsion is prepared by a method comprising the following process:

[0015] Mix an organic solvent solution of ergosterol and an aqueous solution of soy protein isolate, and subject the mixture to shear treatment to obtain the mixed emulsion.

[0016] For the preparation method as described above, the mass ratio of ergosterol to soy protein isolate is 10:1 - 3.

[0017] For the preparation method as described above, before centrifuging, an organic solvent separation treatment is further included for the precursor of the ergosterol nano-dispersion.

[0018] For the preparation method as described above, in the organic solvent solution of ergosterol, the concentration of ergosterol is 0.4 - 0.6% w / v.

[0019] For the preparation method as described above, in the aqueous solution of soy protein isolate, the concentration of soy protein isolate is 1.5 - 2.5% w / v.

[0020] For the preparation method as described above, the conditions of the homogenization treatment are 70 - 90 MPa for 2 - 4 cycles.

[0021] For the preparation method as described above, the rotation speed of the centrifuging is 8000 - 9000 rpm, and the time is 8 - 12 min.

[0022] For the preparation method as described above, the rotation speed of the shear treatment is 8000 - 12000 rpm, and the time is 1 - 5 min.

[0023] The present application also provides an ergosterol nano-dispersion solution, which comprises the ergosterol nano-dispersion described in any one of the above or the ergosterol nano-dispersion prepared by the preparation method described in any one of the above and a solvent.

[0024] The present application also provides a lipid-lowering drug, which comprises the ergosterol nano-dispersion described in any one of the above, or the ergosterol nano-dispersion prepared by the preparation method described in any one of the above, or the above-mentioned ergosterol nano-dispersion solution.

[0025] For the ergosterol nano-dispersion provided by the present application, by defining the composition with ergosterol as the core material and soy protein isolate as the wall material, and the relevant parameters of the particle size being 250 - 400 nm and the PDI being 0.034 - 0.106, the dispersibility, homogeneity, and bioaccessibility of ergosterol in water are effectively improved. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 It is the particle size distribution diagram of the ergosterol nano-dispersion in Example 2 of the present application;

[0027] Figure 2 It is the bioavailability comparison diagram of the ergosterol nano-dispersion in Example 2 of the present application and the ergosterol in Comparative Example 1;

[0028] Figure 3 It is the dispersion effect comparison diagram of the ergosterol nano-dispersion in Example 2 of the present application and the ergosterol in Comparative Example 1;

[0029] Figure 4 It is the in vitro lipid-lowering comparison diagram of the ergosterol nano-dispersion in Example 2 of the present application and the ergosterol in Comparative Example 1;

[0030] Figure 5 It is the in vivo lipid-lowering comparison diagram of the ergosterol nano-dispersion in Example 2 of the present application and the ergosterol in Comparative Example 1. DETAILED DESCRIPTION OF THE EMBODIMENTS

[0031] To make the objectives, technical solutions, and advantages of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are some, but not all, of the embodiments of the present invention. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts shall fall within the protection scope of the present invention.

[0032] Due to its extremely low water solubility, ergosterol is difficult to be uniformly dispersed in a conventional aqueous phase system, which limits its applications in the fields of food, medicine, etc. In addition, the bioaccessibility of ergosterol is poor, resulting in low efficiency during the human digestion and absorption process, further reducing the exertion of its physiological activity.

[0033] The inventors analyzed that the problem of uneven dispersion of ergosterol in water could be improved by dispersing ergosterol. During the research process, the inventors found that the use of embedding operation for dispersion treatment had a greater positive impact on the improvement effect. However, how to select a more suitable wall material and control the particle size and PDI of the dispersed particles are the keys to improving the uniform dispersion degree of ergosterol.

[0034] Based on this, the present application provides an ergosterol nano-dispersion, which includes an ergosterol core material and a soy protein isolate wall material that wraps at least part of the surface of the ergosterol core material. The particle size of the dispersion is 250 - 400 nm, and the PDI of the dispersion is 0.034 - 0.106.

[0035] Specifically, soy protein isolate has hydrophilic and hydrophobic regions, which enables it to reduce the surface tension of water and oil and form a stable emulsion in water, thereby playing a role in stabilizing the dispersion system. Soy protein isolate can wrap the hydrophobic ergosterol. By controlling the particle size of the dispersion to be 250 - 400 nm and the PDI to be 0.034 - 0.106, an ergosterol nano-dispersion with better dispersion and uniformity in water can be formed.

[0036] The soy protein isolate that wraps at least part of the surface of the ergosterol in the nano-dispersion can better resist degradation and metabolism in the digestive tract, thereby improving its stability and increasing its effectiveness in the body. Moreover, the nano-sized particles of this nano-dispersion can increase the contact area with intestinal epithelial cells, thus better promoting the absorption of ergosterol by the human body.

[0037] In addition to the above effects, the ergosterol nano-dispersion of the present application also has the advantage of long-term stability. Therefore, the dispersion also has a longer shelf life.

[0038] The inventors found that when the dispersed particles of the dispersion are spherical or quasi-spherical, the dispersion, uniformity, and bioaccessibility of the dispersion are significantly improved.

[0039] The present application also provides a preparation method of the aforementioned ergosterol dispersion, including the following steps:

[0040] After homogenizing a mixed emulsion including ergosterol and soy protein isolate, a precursor of the ergosterol nano-dispersion is obtained. After centrifuging the precursor of the ergosterol nano-dispersion, the ergosterol nano-dispersion is obtained.

[0041] Specifically, homogenizing a mixed emulsion comprising ergosterol and soy protein isolate can promote the formation of a dispersion and improve the homogeneity of the dispersion. After centrifuging the resulting ergosterol nano-dispersion precursor, the unentrapped ergosterol and protein precipitate will adhere to the container wall. After separating these impurities, an ergosterol nano-dispersion with better dispersibility and bioaccessibility is obtained.

[0042] In a specific embodiment, a mixed emulsion can be obtained by mixing an organic solvent solution of ergosterol and an aqueous solution of soy protein isolate and subjecting the mixture to shear treatment, which can result in better dispersibility and homogeneity of the dispersion.

[0043] The present application does not limit the choice of organic solvent, as long as it can dissolve ergosterol. Exemplarily, it can be at least one of ethyl acetate, dichloromethane, and n-hexane. When making a specific selection, the choice can be made according to the dissolving effect of the specific solvent on ergosterol.

[0044] To further improve the dispersibility, homogeneity, and bioaccessibility of the dispersion, the mass ratio of ergosterol to soy protein isolate is 10:1 - 3.

[0045] In a specific embodiment, before centrifugation, the ergosterol dispersion precursor can also be subjected to organic solvent separation treatment, which can remove the existing organic solvent from the ergosterol dispersion, ensure harmless absorption by the human body, and more effectively improve the bioaccessibility of the dispersion.

[0046] The present application does not limit the operation of organic solvent separation treatment. For example, the organic solvent can be removed by evaporation in a rotary evaporator under vacuum, or it can be removed by natural volatilization of the organic solvent. The present application also does not limit the temperature during organic solvent separation treatment. When making a specific selection, the choice can be made according to the efficiency of organic solvent removal.

[0047] The inventors found that when the concentration of ergosterol in the organic solvent solution of ergosterol and the concentration of soy protein isolate in the aqueous solution of soy protein isolate are within the following ranges, the dispersibility, homogeneity, and bioaccessibility of the dispersion are better. Specifically, the concentration of ergosterol in the organic solvent solution of ergosterol is 0.4 - 0.6% w / v, and the concentration of soy protein isolate is 1.5 - 2.5% w / v, where w / v represents the ratio of the mass of the solute to the volume of the solution.

[0048] To further improve the homogeneity of the dispersion, the homogenization treatment can be carried out using a high-pressure homogenizer, and the conditions for the homogenization treatment are 70 - 90 Mpa for 2 - 4 cycles.

[0049] In addition, in order to further improve the efficiency of centrifugation, a high-speed centrifuge can be selected as the centrifugation equipment, with a rotation speed of 8000 - 9000 rpm and a time of 8 - 12 min for centrifugation.

[0050] The present application does not limit the equipment for shear treatment. For example, the equipment can be an ultrasonic shearer or a high-speed shearer. When making a specific selection, it can be chosen according to the dispersion effect of the dispersion.

[0051] For a high-speed shearer, when the rotation speed for shear treatment is 8000 - 12000 rpm and the time is 1 - 5 min, the dispersion effect of the dispersion is better.

[0052] The present application also provides an ergosterol nano-dispersion solution, which includes the aforementioned ergosterol nano-dispersion or the ergosterol nano-dispersion prepared by the aforementioned preparation method and a solvent.

[0053] Among them, the solvent can be any liquid that has no strong toxic and side effects on the human body and can be miscible with water. For example, it can be water or ethanol.

[0054] The present application does not limit the method for preparing the ergosterol nano-dispersion solution from the ergosterol nano-dispersion. In a specific embodiment, it can be to add water to the ergosterol nano-dispersion for dilution, and then obtain the ergosterol nano-dispersion solution after high-speed shearing. The dispersion in this solution has better dispersion and is more suitable for lipid-lowering drugs.

[0055] The present application also provides a lipid-lowering drug, which includes the aforementioned ergosterol nano-dispersion, or the ergosterol nano-dispersion prepared by the aforementioned preparation method, or the aforementioned ergosterol nano-dispersion solution. This lipid-lowering drug can be any drug with lipid-lowering effects in the pharmaceutical field. This lipid-lowering drug has better lipid-lowering effects and a wider scope of application.

[0056] Example 1

[0057] The preparation method of this ergosterol nano-dispersion includes the following steps:

[0058] 1) Dissolve ergosterol in dichloromethane to obtain an ergosterol solution with a concentration of 0.4% w / v;

[0059] 2) Dissolve soy protein isolate in water to obtain a soy protein isolate solution with a concentration of 1.5% w / v;

[0060] 3) Mix the ergosterol solution and the soy protein isolate solution evenly according to a mass ratio of 10:1 for ergosterol and soy protein isolate, and use a high-speed shearer to shear for 1 min at 8000 rpm to obtain a mixed emulsion;

[0061] 4) Homogenize the mixed emulsion using a high-pressure homogenizer under the condition of 70 MPa for 2 cycles, and then evaporate and remove the organic solvent at 40 °C using a vacuum rotary evaporator to obtain the ergosterol nanodispersion precursor;

[0062] 5) Centrifuge the ergosterol nanodispersion precursor at 8000 rpm for 8 min using a high-speed centrifuge to remove the unentrapped ergosterol and protein precipitate, and finally obtain the ergosterol nanodispersion.

[0063] Example 2

[0064] The preparation method of the ergosterol nanodispersion includes the following steps:

[0065] 1) Dissolve ergosterol in dichloromethane to obtain an ergosterol solution with a concentration of 0.5% w / v;

[0066] 2) Dissolve soy protein isolate in water to obtain a soy protein isolate solution with a concentration of 2% w / v;

[0067] 3) Mix the ergosterol solution and the soy protein isolate solution evenly according to the mass ratio of ergosterol to soy protein isolate of 10:2, and shear for 1.5 min using a high-speed shearer under the condition of 10000 rpm to obtain a mixed emulsion;

[0068] 4) Homogenize the mixed emulsion using a high-pressure homogenizer under the condition of 80 MPa for 3 cycles, and then evaporate and remove the organic solvent at 45 °C using a vacuum rotary evaporator to obtain the ergosterol nanodispersion precursor;

[0069] 5) Centrifuge the ergosterol nanodispersion precursor at 8500 rpm for 10 min using a high-speed centrifuge to remove the unentrapped ergosterol and protein precipitate, and finally obtain the ergosterol nanodispersion.

[0070] Example 3

[0071] The preparation method of the ergosterol nanodispersion includes the following steps:

[0072] 1) Dissolve ergosterol in dichloromethane to obtain an ergosterol solution with a concentration of 0.6% w / v;

[0073] 2) Dissolve soy protein isolate in water to obtain a soy protein isolate solution with a concentration of 2.5% w / v;

[0074] 3) Mix the ergosterol solution and the soy protein isolate solution evenly according to the mass ratio of ergosterol to soy protein isolate of 10:3, and shear for 2 min using a high-speed shearer under the condition of 12000 rpm to obtain a mixed emulsion;

[0075] 4) The mixed emulsion was homogenized for 4 cycles under the condition of 100 MPa using a high-pressure homogenizer, and then the organic solvent was removed by evaporation at 50 °C using a rotary evaporator under vacuum to obtain a precursor of ergosterol nanodispersion;

[0076] 5) The precursor of ergosterol nanodispersion was centrifuged at 9000 rpm for 12 min using a high-speed centrifuge to remove unentrapped ergosterol and protein precipitates, and finally an ergosterol nanodispersion was obtained.

[0077] Example 4

[0078] The preparation method of the ergosterol nanodispersion in this example was basically the same as that in Example 2, except that the mass ratio of ergosterol to soy protein isolate was 10:4.

[0079] Example 5

[0080] The preparation method of the ergosterol nanodispersion in this example was basically the same as that in Example 2, except that the concentration of the ergosterol solution was 0.2%.

[0081] Example 6

[0082] The preparation method of the ergosterol nanodispersion in this example was basically the same as that in Example 2, except that the concentration of the soy protein isolate solution was 1%.

[0083] Comparative Example 1

[0084] This comparative example was untreated ergosterol.

[0085] Test Example 1

[0086] The particle size, PDI, encapsulation rate and bioavailability of the ergosterol nanodispersion of the above examples and the ergosterol of Comparative Example 1 were measured, and the measurement results are shown in Table 1. Among them, the particle size and PDI were measured at 25 °C using a dynamic light scattering particle size analyzer by diluting the dispersion to a suitable concentration with deionized water.

[0087] Figure 1 This is the particle size distribution diagram of the ergosterol nanodispersion of Example 2 of this application.

[0088] From Figure 1 it can be seen that the particle size of the ergosterol nanodispersion mainly concentrated between 250 and 400 nm. Measured by the above method, the average particle size of this dispersion was 297 nm, and the particle size of the dispersion was uniform, indicating that the dispersion was more uniform.

[0089] Encapsulation rate: The content of free ergosterol obtained by extraction with petroleum ether and the total ergosterol content obtained by extraction after ultrasonic treatment were measured at a wavelength of 282 nm, and then measured by calculating through the following formula:

[0090] .

[0091] Bioavailability: The ergosterol nanodispersions of the above examples and the ergosterol of Comparative Example 1 were subjected to simulated in vitro digestion. After the digestion, the mixtures were centrifuged at 7500×g for 50 min, the supernatants were collected, and the concentration of ergosterol in the micelles was measured at a wavelength of 282 nm. The concentration was then calculated and determined using the following formula:

[0092] .

[0093] Figure 2 This is a comparison chart of the bioavailability of the ergosterol nanodispersion of Example 2 of the present application and the ergosterol of Comparative Example 1.

[0094] Depend on Figure 2 It can be seen that the bioavailability of the ergosterol nanodispersion of Example 2 is much higher than that of the ergosterol of Comparative Example 1, indicating that the dispersion has better bioaccessibility.

[0095] Table 1

[0096]

[0097] As can be seen from Table 1, the particle size and PDI of the ergosterol dispersion of the present application are smaller, and the embedding rate and bioavailability are higher, indicating that the dispersion of the present application has higher dispersibility, uniformity and better bioaccessibility.

[0098] Test Example 2

[0099] The dispersion effects of the ergosterol nanodispersion of Example 2 and the ergosterol of Comparative Example 1 were measured. The dispersion effects were measured by dissolving the ergosterol dispersion of Comparative Example 2 and the ergosterol of Comparative Example 1 in deionized water, taking photos and comparing them.

[0100] Figure 3 This is a comparison chart of the dispersion effects of ergosterol in Example 2 of the present application and Comparative Example 1.

[0101] Depend on Figure 3 It can be seen that the ergosterol of Comparative Example 1 is difficult to disperse in water, while the ergosterol dispersion of Example 2 is more uniformly dispersed in water.

[0102] Test Example 3

[0103] The in vitro lipid-lowering effect and in vivo lipid-lowering effect of the ergosterol nanodispersion of the above example and the ergosterol of comparative example 1 were measured. The in vitro lipid-lowering effect was measured by: 3T3-L1 cells in the logarithmic growth phase were cultured at 1×10 4Inoculate at a uniform seeding density of cells per well into a 6-well culture plate, and place it in an incubator at 37 °C and 5% CO₂ until the cells are completely confluent. Use an adipogenic induction differentiation medium to induce the differentiation of 3T3-L1 cells into adipocytes. During the experiment, ergosterol nano-dispersions and ergosterol aqueous solutions are added to different induction differentiation media respectively; after the induction of differentiation is completed, the 3T3-L1 cells are lysed, and the triglyceride content in the cells is measured.

[0104] Method for measuring the lipid-lowering effect in vivo: 16 male SPF-grade C57BL / 6J strain mice at 5 weeks old, with a body weight of 16 - 20 g, are fed with a basal diet for one week for adaptation before the formal experiment starts. After the adaptation feeding is completed, the mice are randomly divided into 2 groups. The first group is fed a high-fat diet containing 1% ergosterol, and the second group is fed a high-fat diet containing 1% ergosterol nano-dispersion. During the experiment, the mice in each group are allowed to eat and drink freely, and the feed is changed every day. After 12 weeks of feeding, blood is taken from the eyeballs, and the cholesterol content in the serum is measured.

[0105] Figure 4 This is a comparison chart of the in vitro lipid-lowering effects of the ergosterol nano-dispersion in Example 2 of this application and the ergosterol in Comparative Example 1.

[0106] From Figure 4 it can be seen that the triglyceride content in the ergosterol group is significantly higher than that in the ergosterol nano-dispersion group, indicating that the in vitro lipid-lowering effect of the dispersion is better and the bioaccessibility is higher.

[0107] Figure 5 This is a comparison chart of the in vivo lipid-lowering effects of the ergosterol nano-dispersion in Example 2 of this application and the ergosterol in Comparative Example 1.

[0108] From Figure 5 it can be seen that the cholesterol content in the ergosterol group is significantly Show higher than that in the ergosterol nano-dispersion group, indicating that the in vivo lipid-lowering effect of the dispersion is better and the bioaccessibility is higher.

[0109] Therefore, the triglyceride content in the in vitro experimental cells treated with the ergosterol nano-dispersion of this application is lower, and the cholesterol content in the in vivo experimental serum is also lower, indicating that the dispersion of this application has a better lipid-lowering effect and better bioaccessibility.

[0110] Finally, it should be noted that: the above embodiments are only used to illustrate the technical solutions of the present invention, and are not intended to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those of ordinary skill in the art should understand that: they can still modify the technical solutions recorded in the foregoing embodiments, or perform equivalent replacements on some or all of the technical features; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A ergosterol nano-dispersion, characterized in that, It includes ergosterol as the core material and soy protein isolate as the wall material that wraps at least part of the surface of the ergosterol core material. The particle size of the dispersion is 250 - 400 nm, and the PDI of the dispersion is 0.034 - 0.

106.

2. The dispersion according to claim 1, wherein The dispersed particles of the dispersion are spherical or quasi-spherical.

3. A method for preparing the dispersion according to claim 1 or 2, characterized in that, It includes the following steps: After homogenizing the mixed emulsion including ergosterol and soy protein isolate, an ergosterol nano-dispersion precursor is obtained. After centrifuging the ergosterol nano-dispersion precursor, an ergosterol nano-dispersion is obtained.

4. The preparation method according to claim 3, characterized in that, The mixed emulsion is prepared by a method including the following process: Mix the organic solvent solution of ergosterol and the aqueous solution of soy protein isolate, and perform shear treatment on the mixture to obtain the mixed emulsion.

5. The preparation method according to claim 3 or 4, characterized in that, The mass ratio of ergosterol to soy protein isolate is 10:1 - 3.

6. The preparation method according to any one of claims 3-5, characterized in that, Before centrifuging, it further includes performing organic solvent separation treatment on the ergosterol nano-dispersion precursor.

7. The preparation method according to any one of claims 4 to 6, characterized in that, In the organic solvent solution of ergosterol, the concentration of ergosterol is 0.4 - 0.6% w / v; and / or, In the aqueous solution of soy protein isolate, the concentration of soy protein isolate is 1.5 - 2.5% w / v.

8. The preparation method according to any one of claims 4-7, characterized in that, The conditions of the homogenization treatment are homogenizing at 70 - 90 MPa for 2 - 4 cycles; and / or, The rotation speed of the centrifugation is 8000 - 9000 rpm, and the time is 8 - 12 min; and / or, The rotation speed of the shear treatment is 8000 - 12000 rpm, and the time is 1 - 5 min.

9. A ergosterol nano-dispersion solution, characterized in that, It includes the ergosterol nano-dispersion described in Claim 1 or 2 or the ergosterol nano-dispersion prepared by the preparation method described in any one of Claims 3 - 8 and a solvent.

10. A lipid-lowering drug, characterized in that, It includes the ergosterol nano-dispersion described in Claim 1 or 2, or the ergosterol nano-dispersion prepared by the preparation method described in any one of Claims 3 - 8, or the ergosterol nano-dispersion solution described in Claim 9.

Images